Court clears Pfizer to move ahead with Remicade biosimilar; McDonald’s yanks activity trackers over skin irritation; California drug-pricing bill pulled
Five things for pharma marketers to know: Monday, July 18, 2016
Roche’s blood cancer drug fails to meet trial goal; the FDA says Valeant’s psoriasis drug carries risk of suicide; Facebook tests disappearing messages
Five things for pharma marketers to know: Wednesday, May 18, 2016
GSK won’t patent drugs sold in low-income countries; experimental dermatitis therapy met Phase III endpoints; the FDA issues biosimilar labeling guidance
Drugmakers move to counteract expiring patents with new respiratory drugs
Symptom-driven care is falling out of favor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.
Five things for pharma marketers to know: Friday, March 25, 2016
Gilead to pay Merck $200 million in HCV patent infringement suit; some patients aren’t prescribed blood thinners; the FDA issues generic opioid guidance
Five things for pharma marketers to know: Tuesday, August 25
US patent office declines to review two Ampyra patents; the FDA expands indication for Promacta; the Biosimilars Council argues against CMS proposal for biosimilar coding